Cevdet Serkan GÖKKAYA, Cüneyt ÖZDEN, Binhan Kağan AKTAŞ, Hüseyin Cihan DEMİREL, Özer GÜZEL, Mehmet KARABAKAN, Akif Ersoy ERKMEN, Çetin Volkan ÖZTEKİN, Ali MEMİŞ

The correlation between metabolic syndrome and lower urinary tract symptoms in females

To evaluate the association between lower urinary tract symptoms (LUTS) and metabolic syndrome (MS) in women. Materials and methods: A total of 155 women with LUTS were included in the study. LUTS were evaluated using the International Prostate Symptom Score (IPSS) and the Bristol Female Lower Urinary Tract Symptoms (BFLUTS) questionnaire. Besides total IPSS, voiding and storage IPSS were calculated separately. Diagnosis of MS was made according to the consensus report of the International Diabetes Foundation. The patients were classified into 3 groups: those without MS (group 1), those with 3 risk factors of MS (group 2), and those with more than 3 risk factors of MS (group 3). The groups were compared regarding IPSS and BFLUTS data. Results: Of the patients, 37.4% (n = 58) had MS, while 62.6% (n = 97) did not. There were significant differences between group 1 and group 3 regarding BFLUTS-FS (filling symptoms), BFLUTS-QoL (quality of life), storage IPSS, and total IPSS. However, concerning BFLUTS-VS (voiding symptoms), BFLUTS-sex, and voiding IPSS, there was not any difference among the 3 groups. Conclusion: The results of our study have shown that women with more than 3 MS components might have more storage symptoms than women without MS.

Anahtar Kelimeler:

Key words: Female, lower urinary tract symptoms, metabolic syndrome

The correlation between metabolic syndrome and lower urinary tract symptoms in females

Keywords:

Key words: Female, lower urinary tract symptoms, metabolic syndrome,

PDF

___

Meigs JB, Rutter MK, Sullivan LM, Fox CS, D’Agostino RB Sr, Wilson PW. Impact of insulin resistance on risk of type 2 diabetes and cardiovascular disease in people with metabolic syndrome. Diabetes Care 2007; 30: 1219–25.
Wilson PW, D’Agostino RB, Parise H, Sullivan L, Meigs JB. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 2005; 112: 3066–72.
Ayvaz DNÇ, Kılınç FN, Paç FA, Çakal E. Anthropometric measurements and body composition analysis of obese adolescents with and without metabolic syndrome. Turk J Med Sci 2011; 41: 267–74.
Ecemiş GC, Kahraman H, Nural MS, Aslan HS, Atmaca A. The relationship between insulin resistance and carotid artery intima-media thickness in obese and morbidly obese women. Turk J Med Sci 2012; 42: 1121–8.
Kjeldsen SE, Naditch-Brule L, Perlini S, Zidek W, Farsang C. Increased prevalence of metabolic syndrome in uncontrolled hypertension across Europe: the Global Cardiometabolic Risk Profile in Patients with hypertension disease survey. J Hypertens 2008; 26: 2064–70.
Gündogan K, Bayram F, Capak M, Tanriverdi F, Karaman A, Ozturk A et al. Prevalence of metabolic syndrome in the Mediterranean region of Turkey: evaluation of hypertension, diabetes mellitus, obesity, and dyslipidemia. Metab Syndr Relat Disord 2009; 7: 427–34.
Fox CS, Massaro JM, Hoffmann U, Pou KM, MaurovichHorvat P, Liu CY et al. Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation 2007; 116: 39–
Akkiprik M, Sertoğlu FÖ, Çağlayan S, Aral C, Özışık G, Atabey Z et al. Association of ACP1 genotypes and clinical parameters in patients with metabolic syndrome. Turk J Med Sci 2011; 41: 533–41.
Isomaa B, Almgren P, Tuomi T, Forsén B, Lahti K, Nissén M et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24: 683–9.
Onat A, Ceyhan K, Başar O, Erer B, Toprak S, Sansoy V. Metabolic syndrome: major impact on coronary risk in a population with low cholesterol levels a prospective and crosssectional evaluation. Atherosclerosis 2002; 165: 285–92.
Gammack JK. Lower urinary tract symptoms. Clin Geriatr Med 2010; 26: 249–60.
Fultz NH, Herzog AR. Epidemiology of urinary symptoms in the geriatric population. Urol Clin North Am 1996; 23: 1–10.
Alexander CM, Landsman PB, Grundy SM. The influence of age and body mass index on the metabolic syndrome and its components. Diabetes Obes Metab 2008; 10: 246–50.
Gorbachinsky I, Akpinar H, Assimos DG. Metabolic syndrome and urologic diseases. Rev Urol 2010; 12: 157–80.
Demir O, Akgul K, Akar Z, Cakmak O, Ozdemir I, Bolukbasi A et al. Association between severity of lower urinary tract symptoms, erectile dysfunction and metabolic syndrome. Aging Male 2009; 12: 29–34.
Hammarsten J, Högstedt B, Holthuis N, Mellström D. Components of the metabolic syndrome-risk factors for the development of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis 1998; 1: 157–62.
Tai HC, Chung SD, Ho CH, Tai TY, Yang WS, Tseng CH et al. Metabolic syndrome components worsen lower urinary tract symptoms in women with type 2 diabetes. J Clin Endocrinol Metab 2010; 95: 1143–50.
Temml C, Obermayr R, Marszalek M, Rauchenwald M, Madersbacher S, Ponholzer A. Are lower urinary tract symptoms influenced by metabolic syndrome? Urology 2009; 73: 544–8.
Alberti KG, Zimmet P, Shaw J. IDF Epidemiology Task Force Consensus Group. The metabolic syndrome--a new worldwide definition. Lancet 2005; 366: 1059–62.
Eom CS, Park JH, Cho BL, Choi HC, Oh MJ, Kwon HT. Metabolic syndrome and accompanying hyperinsulinemia have favorable effects on lower urinary tract symptoms in a generally healthy screened population. J Urol 2011; 186: 175–9. Rohrmann S, Smit E, Giovannucci E, Platz EA. Association between markers of the metabolic syndrome and lower urinary tract symptoms in the Third National Health and Nutrition Examination Survey (NHANES III). Int J Obes 2005; 29: 310–6.
Hammarsten J, Högstedt B. Clinical, anthropometric, metabolic and insulin profile of men with fast annual growth rates of benign prostatic hyperplasia. Blood Pres 1999; 8: 29–
Kupelian V, McVary KT, Kaplan SA, Hall SA, Link CL, Aiyer LP et al. Association of lower urinary tract symptoms and the metabolic syndrome: results from the Boston Area Community Health Survey. J Urol 2009; 182: 616–24.
Wennberg AL, Molander U, Fall M, Edlund C, Peeker R, Milsom I. A longitudinal population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in women. Eur Urol 2009; 55: 783–91.
Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006; 50: 1306–14; discussion 1314–5.
Uzun H, Zorba OÜ. Metabolic syndrome in female patients with overactive bladder. Urology 2012; 79: 72–5.
Hong GS, Shim BS, Chung WS, Yoon H. Correlation between metabolic syndrome and lower urinary tract symptoms of males and females in the aspect of gender-specific medicine: a single institutional study. Korean J Urol 2010; 51: 631–5.
Azadzoi KM. Effect of chronic ischemia on bladder structure and function. Adv Exp Med Biol 2003; 539: 271–80.
Azadzoi KM, Yalla SV, Siroky MB. Oxidative stress and neurodegeneration in the ischemic overactive bladder. J Urol 2007; 178: 710–5.
Cellek S, Rodrigo J, Lobos E, Fernández P, Serrano J, Moncada S. Selective nitrergic neurodegeneration in diabetes mellitus a nitric oxide-dependent phenomenon. Br J Pharmacol 1999; 128: 1804–12.
McVary KT, Razzaq A, Lee C, Venegas MF, Rademaker A, McKenna KE. Growth of the rat prostate gland is facilitated by the autonomic nervous system. Biol Reprod 1994; 51: 99–107.